(Q43242343)

17 November 2017

Cognitive-enhancing effects of aripiprazole: a case report (English)

1 reference

17 November 2017

Armida Mucci

1

0 references

Silvana Galderisi

object named as

Silvana Galderisi

series ordinal

3

0 references

author name string

Giuseppe Piegari

series ordinal

2

1 reference

17 November 2017

language of work or name

1 reference

29 October 2008

1 reference

Clinical Practice and Epidemiology in Mental Health

17 November 2017

1 reference

17 November 2017

4

1 reference

17 November 2017

24

1 reference

https://scigraph.springernature.com/pub.10.1186/1745-0179-4-24

17 November 2017

0 references

cites work

Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2583964

Olanzapine attenuates brain damage after focal cerebral ischemia in vivo

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2583964

The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2583964

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2583964

Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2583964

Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2583964

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2583964

Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2583964

Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2583964

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2583964

Neurocognitive deficit in schizophrenia: a quantitative review of the evidence.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2583964

15 August 2018

Identifiers

DOI

10.1186/1745-0179-4-24

1 reference

Dimensions Publication ID

17 November 2017

0 references

1 reference

17 November 2017

PubMed publication ID

18959801

1 reference